Baseline Laboratory Tests Before Starting Quetiapine
Before initiating quetiapine, obtain: BMI, waist circumference, blood pressure, HbA1c (or fasting glucose), lipid panel, prolactin, liver function tests, urea and electrolytes, complete blood count, and electrocardiogram. 1
Required Baseline Assessments
The 2025 INTEGRATE international guidelines for antipsychotic treatment provide explicit recommendations for pre-treatment monitoring that apply to quetiapine 1:
Metabolic Parameters
- BMI and waist circumference - Essential given quetiapine's association with weight gain
- Blood pressure - Monitor for orthostatic hypotension risk
- HbA1c or glucose - Screen for diabetes risk; fasting glucose preferred but random glucose acceptable if fasting sample cannot be obtained 1
- Lipid panel - Quetiapine can increase cholesterol and triglycerides 2
Laboratory Tests
- Liver function tests - Monitor hepatic function before initiation
- Urea and electrolytes - Establish renal baseline
- Complete blood count - Screen for baseline hematologic abnormalities
- Prolactin level - Establish baseline for future monitoring
Cardiac Assessment
FDA-Specified Monitoring Requirements
The FDA label emphasizes that healthcare providers should check blood sugar before starting quetiapine, particularly in patients with diabetes or diabetes risk factors (obesity, family history) 2. The label also notes that cholesterol and triglycerides should be monitored, as patients may not have symptoms of dyslipidemia 2.
Special Considerations for Pediatric Patients
In children and adolescents, blood pressure monitoring is particularly important as quetiapine can cause increases in this population 2. The same baseline laboratory panel applies, with heightened attention to metabolic parameters given higher vulnerability to weight gain 2.
Common Pitfalls to Avoid
- Don't skip the ECG - A 2026 audit found only 47.8% compliance with baseline ECG monitoring before antipsychotic initiation, representing a significant safety gap 3
- Don't accept non-fasting glucose as final - If initial random glucose is abnormal, prioritize obtaining a fasting sample 1
- Don't delay treatment for perfect fasting conditions - Pragmatically, random glucose can serve as initial screening if fasting samples are difficult to obtain 1
Post-Initiation Monitoring Schedule
After baseline assessment, recheck fasting glucose at 4 weeks, then monitor BMI, waist circumference, and blood pressure weekly for 6 weeks. Repeat the complete metabolic panel at 3 months, then annually thereafter 1.
This comprehensive baseline assessment is critical because quetiapine carries significant cardiometabolic risks including hyperglycemia (potentially leading to ketoacidosis, coma, or death), dyslipidemia, weight gain, orthostatic hypotension, and QT prolongation 2. The FDA label explicitly warns that extremely high blood sugar can lead to coma or death, making baseline glucose assessment non-negotiable 2.